Company Performance - Corcept Therapeutics (CORT) shares have increased by 16.2% over the past month and reached a new 52-week high of $62.98 [1] - Year-to-date, the stock has gained 23.6%, outperforming the Zacks Medical sector, which declined by 2.1%, and the Zacks Medical - Drugs industry, which fell by 7.9% [1] Earnings and Revenue - Corcept has consistently exceeded earnings expectations, reporting an EPS of $0.41 against a consensus estimate of $0.27 in its last earnings report on October 30, 2024, and beating revenue estimates by 6.07% [2] - For the current fiscal year, Corcept is projected to earn $1.84 per share on revenues of $689.04 million, with a year-over-year earnings growth of 36.44% [3] - For the next fiscal year, earnings are expected to rise to $2.84 per share on revenues of $777.04 million, reflecting a year-over-year change of 12.77% [3] Valuation Metrics - Corcept's current valuation metrics indicate a premium, trading at 33.8X current fiscal year EPS estimates compared to the peer industry average of 20.7X [6] - On a trailing cash flow basis, the stock trades at 65X versus an average of 8X for its peer group, suggesting it is not positioned in the top echelon from a value perspective [6] Zacks Rank and Style Scores - Corcept holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, meeting the criteria for potential gains [7] - The stock has a Value Score of C, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of B [6][7] Industry Comparison - AMNEAL PHARMACEUTICALS, INC. (AMRX) is a notable peer with a Zacks Rank of 2 (Buy) and strong style scores across Value, Growth, and Momentum [8] - AMRX has also shown strong earnings performance, beating consensus estimates by 23.08% last quarter, with projected earnings of $0.70 per share on revenues of $2.77 billion for the current fiscal year [9] - The Medical - Drugs industry is positioned in the top 35% of all industries, indicating favorable conditions for both CORT and AMRX [10]

Core Insights - Chuck Jones has extensive experience in equity analysis and investment management, with a focus on technology and life sciences sectors [1] - He has successfully developed strategies for wealth management targeting technology executives and private equity partners [1] - Jones has a strong track record of outperforming industry benchmarks through financial modeling and direct engagement with company leadership [1] Group 1: Career Background - Chuck Jones has a total of twelve years as an equity analyst and sixteen years in various roles at IBM [1] - He has held significant positions at Northern Trust and Atlantic Trust Private Wealth Management, focusing on technology holdings [1] - His early career included a lead analyst role for Internet Security Software at Smith Barney, where he authored comprehensive industry reports [1] Group 2: Skills and Achievements - Jones utilized extensive financial modeling and industry contacts to achieve superior performance over six consecutive years [1] - He has been recognized with multiple sales awards during his tenure at IBM, including a President's award [1] - His educational background includes a B.S. in Industrial Engineering from Stanford University and a Postgraduate Diploma in Economics from the University of Sussex [1]

Core Insights - Corcept Therapeutics announced data from the phase II DAZALS study evaluating dazucorilant for treating amyotrophic lateral sclerosis (ALS) [1] - The study did not meet its primary endpoint, leading to a decline in Corcept's shares in pre-market trading [2] - Year-to-date, Corcept's shares have increased by 85%, contrasting with a 4.6% decline in the industry [3] Study Details - The DAZALS study was a double-blind, placebo-controlled trial assessing two doses of dazucorilant (150 mg and 300 mg) [1] - Patients treated with dazucorilant experienced significantly more gastrointestinal upset compared to the placebo group [4] - An open-label, long-term extension study will continue, with overall survival data expected in March next year [5] Regulatory and Pipeline Updates - The FDA has granted Fast Track Designation to dazucorilant for ALS treatment [7] - Corcept's lead pipeline candidate, relacorilant, is in phase III of the GRACE study for Cushing's syndrome [8] - An NDA for relacorilant in Cushing's syndrome is anticipated to be submitted shortly [10] Additional Studies - Relacorilant is also being evaluated in combination with other drugs for various cancer indications, including a phase III study for platinum-resistant ovarian cancer [11]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

A month has gone by since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 19.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Corcept Beats Q3 Earnings & Sales Estimates, ...

Welcome to my profile!My name is Vincent. I have over three years of experience as a tech-oriented buy-side analyst at a major bank, where I co-managed U.S. equity portfolios with over $700M in assets under management. I’ve worked across both large-cap and small-cap stocks, gaining a deep understanding of financial markets. Fascinated by innovation and its potential, my goal is not only to identify tomorrow's future leaders but also to share and discuss these insights with you.I believe every investor shoul ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for profitable short-term investing, highlighting that trends can reverse unexpectedly, leading to potential losses for investors [1][2]. Group 1: Stock Performance - Corcept Therapeutics (CORT) has shown a solid price increase of 56.7% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - CORT has also experienced an 11% price increase over the last four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 82% of its 52-week high-low range, indicating it may be on the verge of a breakout [5]. Group 2: Fundamental Strength - CORT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like CORT that are on an uptrend supported by strong fundamentals [3]. - It mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [8].